Sign in

BioInformant - Stem Cell Industry News

@bioinformant.bsky.social
181 followers 620 following 238 posts

As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.

PostsRepliesMedia
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 28/09/2026
Anja Health Makes Cord Blood, Cord Tissue and Placenta Banking an Employee Benefit and Invites Other Employers to Join In - bioinformant.com/anja-health-... @anjahealth.bsky.social
bioinformant.com
Anja Health Makes Cord Blood, Cord Tissue and Placenta Banking an Employee Benefit and Invites Other Employers to Join In | BioInformant
Anja Health is offering stem cell banking as an employee benefit and inviting employers to bring cord blood, cord tissue and placenta banking to their teams. LOS ANGELES , CA, UNITED STATES, September...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 20/09/2026
Cord Blood Industry Consolidation Escalates in 2026 - bioinformant.com/cord-blood-i...
bioinformant.com
Cord Blood Industry Consolidation Escalates in 2026 | BioInformant
The cord blood industry had strong growth during the early 2000's. However, the market has matured and consolidated over the past decade.
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 20/09/2026
Cryopraxis, BioNK and Radboudumc Partner to Transfer Cord Blood-Derived NK Cell Technology to Brazil - bioinformant.com/cryopraxis-b... @radboudumc.bsky.social
bioinformant.com
Cryopraxis, BioNK and Radboudumc Partner to Transfer Cord Blood-Derived NK Cell Technology to Brazil | BioInformant
Agreement establishes a phased technology-transfer program for the RNK001/HSPC-NK platform and creates a framework for future CAR-NK development SÃO PAULO, Brazil and NIJMEGEN, the Netherlands — Septe...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 19/09/2026
MUSE Cells Now Available at Longevity Medical Institute® - bioinformant.com/muse-cells-n... As part of its Regenerative Neurology Program, Longevity Medical Institute® is making MUSE cell therapy available to select patients, using cells produced in-house at the Institute’s biotech laboratory.
bioinformant.com
MUSE Cells Now Available at Longevity Medical Institute® | BioInformant
As part of its Regenerative Neurology Program, Longevity Medical Institute® is making MUSE cell therapy available to select patients, using cells produced in-house at the Institute’s biotechnology lab...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 27/08/2026
Greenstone Biosciences Wins Breakthrough T1D Grant to Model Diabetes Using Patient-Derived iPSCs - bioinformant.com/greenstone-b... @greenstonebio.bsky.social @breakthrought1dhq.bsky.social
bioinformant.com
Greenstone Biosciences Wins Breakthrough T1D Grant to Model Diabetes Using Patient-Derived iPSCs | BioInformant
Greenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell Platform PALO ALTO, Calif. –Greenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Pa...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 24/08/2026
New Book “The Language of Healing” Tackles the Patient Education Gap in Regenerative Medicine - bioinformant.com/new-book-the... @longevitymedical8.bsky.social
bioinformant.com
New Book "The Language of Healing" Tackles the Patient Education Gap in Regenerative Medicine | BioInformant
The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely thro...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 23/08/2026
IPS HEART’s iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone - bioinformant.com/ips-heart-se...
bioinformant.com
IPS HEART's iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone | BioInformant
IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies HOUSTON–IPS HEART, Inc., a biopharmaceutical company pioneer...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 22/08/2026
Cell Therapy CDMO Cellipont Bioservices Celebrates Major Manufacturing Milestone: Releases 100th GMP Batch - bioinformant.com/cellipont-bi...
bioinformant.com
Cell Therapy CDMO Cellipont Bioservices Celebrates Major Manufacturing Milestone: Releases 100th GMP Batch | BioInformant
Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility THE WOODLANDS, Texas, July 28, 2026 — Cellipont Bioservices, a cell...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 19/08/2026
Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD - bioinformant.com/aspen-neuros...
bioinformant.com
Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD | BioInformant
SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD0...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 10/08/2026
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - bioinformant.com/stem-cells-f...
bioinformant.com
Top Companies Developing Cell Therapies For Diabetes in 2026
Due to advances in regenerative medicine, these companies are leading the charge to find cell therapies for the treatment for diabetes.
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 04/08/2026
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com/ipsc-derived...
bioinformant.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2026
While iPSCs are commonly used in drug discovery, we remain in the early stages of using iPSC-derived cell therapeutics in humans.
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 04/08/2026
China’s First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing - bioinformant.com/chinas-first...
bioinformant.com
China's First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing | BioInformant
For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for comm...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 27/07/2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - bioinformant.com/kyverna-ther... New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel
bioinformant.com
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel | BioInformant
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 — Kyverna Therapeut...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 23/07/2026
Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform - bioinformant.com/longevity-me... Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration.
bioinformant.com
Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform | BioInformant
Non-invasive nose-to-brain delivery system expands treatment options for patients with neurological disorders as an alternative to intrathecal administration. SAN JOSé DEL CABO, BAJA CALIFORNIA SUR, M...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 17/07/2026
🧬The iPSC field hit its 20th anniversary & the data has never looked stronger. The 6th iPSC Drug Development Summit is the only meeting dedicated to advancing iPSC-based cell therapies end-to-end, from discovery through CMC and regulatory strategy. ter.li/mvj4x7ya
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 15/07/2026
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis - bioinformant.com/medipost-inc...
bioinformant.com
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis | BioInformant
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 15/07/2026
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance - bioinformant.com/porton-advan...
bioinformant.com
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance | BioInformant
CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has bee...
010
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 14/07/2026
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation - bioinformant.com/syntax-bio-a... @appliedstemcell.bsky.social
bioinformant.com
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation | BioInformant
The companies will generate data using Applied StemCell’s induced pluripotent stem cell technologies and Syntax Bio’s Cellgorithm™ platform to support application discovery and development CHICAGO & M...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 12/07/2026
Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies - bioinformant.com/cartherics-a...
bioinformant.com
Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies | BioInformant
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, an...
020
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 11/07/2026
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy - bioinformant.com/unixell-biot...
bioinformant.com
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy | BioInformant
SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 10/07/2026
Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain - bioinformant.com/cord-for-lif...
bioinformant.com
Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain | BioInformant
ALTAMONTE SPRINGS, Fla. — In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment...
010
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 09/07/2026
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions - bioinformant.com/roosterbio-a... @appliedstemcell.bsky.social
bioinformant.com
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions | BioInformant
Partnership pairs Applied StemCell’s induced pluripotent stem cell technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems to accelerate development and manufacturing ...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 08/07/2026
BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients - bioinformant.com/bbg-mobile-l...
bioinformant.com
BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients | BioInformant
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advan...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 08/07/2026
Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation - bioinformant.com/anja-health-...
bioinformant.com
Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation | BioInformant
More Than 100 Years of Combined Experience Supporting Families and the Future of Regenerative Medicine LOS ANGELES, CA, UNITED STATES, June 16, 2026 — Anja Health, a leading provider of newborn stem c...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 07/07/2026
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers - bioinformant.com/roosterbio-a... Partnership gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors.
bioinformant.com
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers | BioInformant
Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, transla...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 05/07/2026
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform - bioinformant.com/inmune-bio-a... @anthonynolan.bsky.social
bioinformant.com
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform | BioInformant
LONDON, UK and BOCA RATON, FL, — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell regist...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 02/07/2026
Pivotal Trends Impacting the Global Cord Blood and Tissue Industry in 2026 - bioinformant.com/cord-blood-t...
bioinformant.com
Pivotal Trends Impacting the Global Cord Blood Industry in 2026
There are six pivotal cord blood trends impacting that are impacting the stem cell banking industry in 2026. Curious to know what they are?
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 01/07/2026
Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs - bioinformant.com/osakas-cell-...
bioinformant.com
Osaka's Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs | BioInformant
Japanese government-certified clinic applies ISCT-compliant flow-cytometry release criteria to patient-specific adipose-derived stem cell cultures, serving patients from approximately 20 countries OSA...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 30/06/2026
Cord Blood Industry Consolidation Escalates in 2026 - bioinformant.com/cord-blood-i...
bioinformant.com
Cord Blood Industry Consolidation Escalates in 2026 | BioInformant
The cord blood industry had strong growth during the early 2000's. However, the market has matured and consolidated over the past decade.
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 29/06/2026
Hopstem’s iPSC-derived neural progenitor cell injection earns FDA RMAT designation for chronic stroke - bioinformant.com/hopstems-fda...
bioinformant.com
Hopstem’s iPSC-derived neural progenitor cell injection earns FDA RMAT designation for chronic stroke | BioInformant
HOUSTON, June 03, 2026 – Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced ...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 28/06/2026
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison - bioinformant.com/fujifilm-cel...
bioinformant.com
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison | BioInformant
Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell development and manufacturing New facility is part of a $200 million investment by...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 20/06/2026
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting - bioinformant.com/factor-biosc... @asgct.bsky.social
bioinformant.com
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting | BioInformant
Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 03/06/2026
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - bioinformant.com/stem-cells-f... @evotec.bsky.social @novonordisk.bsky.social @elilillyandcompany.bsky.social
bioinformant.com
Top Companies Developing Cell Therapies For Diabetes in 2026
Due to advances in regenerative medicine, these companies are leading the charge to find cell therapies for the treatment for diabetes.
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 03/06/2026
L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis - bioinformant.com/l2-bio-llc-l...
bioinformant.com
L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis | BioInformant
Innovative Participant-Funded Study Harnesses Enhanced Autologous Adipose-Derived Stem Cells to Combat Degenerative Joint Disease ESCAZU, COSTA RICA, June 1,  2026 — L2 Bio, LLC has formally announced...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 27/05/2026
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - bioinformant.com/ernexa-thera...
bioinformant.com
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | BioInformant
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value CAMBRIDGE, Mass., May 06, 2026 — Ernexa Therapeutics (Nasdaq:...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 26/05/2026
FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media - bioinformant.com/fujifilm-bio...
bioinformant.com
FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | BioInformant
Collaboration results in platform to help researchers overcome challenges in MSC research NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled wi...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 18/05/2026
Cartherics and Catalent Expand Commercial License Agreement - bioinformant.com/cartherics-a...
bioinformant.com
Cartherics and Catalent Expand Commercial License Agreement | BioInformant
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, an...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 01/05/2026
Pluristyx, Inc. and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC) bioinformant.com/pluristyx-qk...
bioinformant.com
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC) | BioInformant
SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free grow...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 16/04/2026
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges - Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies, directly applicable to biotech & pharma iPSC programs. bioinformant.com/cell-easy-ip...
bioinformant.com
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges | BioInformant
Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 A...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 08/04/2026
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China - bioinformant.com/roosterbio-a...
bioinformant.com
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China | BioInformant
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillm...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 05/04/2026
Key Events in the Evolution of iPSC Products that You Need to Know - bioinformant.com/key-events-i...
bioinformant.com
Key Events in the Evolution of iPSC Products that You Need to Know | BioInformant
Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the follow...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 05/04/2026
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases - bioinformant.com/catalent-and...
bioinformant.com
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases | BioInformant
TAMPA, Fla. and CAMBRIDGE, Mass., March 11, 2026 – GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the developmen...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 30/03/2026
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform - bioinformant.com/gameto-licen... @harvardmed.bsky.social @wyssinstitute.bsky.social
bioinformant.com
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform | BioInformant
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease AUSTIN, Texas,...
020
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 17/03/2026
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials - bioinformant.com/longevity-me...
bioinformant.com
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials | BioInformant
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenc...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 17/03/2026
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing - bioinformant.com/green-elepha...
bioinformant.com
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing | BioInformant
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is i...
001
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 16/03/2026
Congrats to the REPROCELL team on launching its new StemEdit Platform, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. Read more: bioinformant.com/reprocell-st... #ipscells #geneediting #ai
001
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 13/03/2026
Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers - bioinformant.com/longevity-me... @longevitymedical8.bsky.social
bioinformant.com
Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers | BioInformant
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of al...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 11/03/2026
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease - bioinformant.com/cytonome-sum...
bioinformant.com
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease | BioInformant
March 11, 2026,  Lexington, MA / United States — Cytonome-ST today congratulated Sumitomo Pharma Co., Ltd. following the company’s announced receipt of regulatory approval for the world’s first iPS ce...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 10/03/2026
10 Biotherapies Books From AABB To Add To Your Reading List In 2026 - bioinformant.com/10-biotherap...
bioinformant.com
10 Biotherapies Books From AABB To Add To Your Reading List In 2026 | BioInformant
There is no better time to put together your biotherapies reading list for 2026! In partnership with AABB (Association for the Advancement of Blood C Biotherapies), BioInformant shares 10 must-have te...
000
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 09/03/2026
REPROCELL Introduces StemEdit Platform: AI-Designed Genome Editors & Hypoimmune iPSC Lines - bioinformant.com/reprocell-st... @reprocell.bsky.social
bioinformant.com
REPROCELL Introduces StemEdit Platform AI-Designed Genome Editors & Hypoimmune iPSC Lines | BioInformant
REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates...
000